LAMP2 and Alzheimer disease: Initially, the pilot study, including subjects having an AD CSF core biomarker profile or a normal profile (controls), showed increased CSF concentrations of several proteins, AP2B1, CTSB, GM2A, LAMP2, and ubiquitin, in AD compared to controls.